Action Points

Explain to interested patients that two studies showed that blacks with endometrial cancer have worse outcomes even when they receive care that is similar to that of whites.

Note that the findings were based on retrospective analyses of data, not a randomized clinical trial.

These findings were reported at a medical conference and as a published abstract and should be considered preliminary until they appear in a peer-reviewed journal.

TAMPA, Fla., March 13 -- Blacks with uterine cancers have an increased risk for death and recurrence, even when they receive the same level of care as white women, suggested two studies reported here.

Review of a government database revealed a 54% increased mortality risk for blacks after adjustment for all known prognostic factors, Jason D. Wright, M.D., of Columbia University, said at the Society of Gynecologic Oncologists meeting.

"There tends to be a difference in the type of tumors that African-American women have compared to Caucasian women," said Dr. Wright. "But even when adjusting for that, it doesn't completely explain the survival difference we're seeing.

"That suggests to us that there is probably some intrinsic difference in the tumors in African-American women that is causing this worse survival."

In the other study, there was an 11-fold higher risk of recurrence in black versus white women with stage I endometrial cancer, despite enrollment in a clinical trial that employed uniform standards of care, reported by George Maxwell, M.D., of Walter Reed Army Medical Center in Washington.

Black women with endometrial cancer have poorer outcomes compared with other racial and ethnic groups, a difference often attributed to disparities in access to healthcare services and in process of care. Whether biologic factors contribute to the outcome differences has remained unclear, said Dr. Wright.

Continuing the examination of outcome differences, investigators reviewed data from the Surveillance, Epidemiology, and End Results (SEER) program. The review identified 76,953 new cases of invasive uterine cancer from 1988 to 2004. The total included 66,829 white women, 4,940 black women, and 5,184 women of other racial and ethnic groups.

A comparison of histologic findings showed that 89% of white women had endometroid tumors, 9% had sarcomas, and 2% had serous/clear cell cancer. Among black women, endometrioid tumors accounted for 70% all the cancers, whereas sarcomas made up 26% of the total and serous/clear cell 4% (P<0.0001).

Examination of the care patients received showed that 22% of white women and 23% of black women had adjuvant radiation therapy, and 40% of both racial groups had lymphadenectomy.

In a multivariate analysis, after adjusting for all other known prognostic factors including stage and histology, black women had a relative risk of mortality of 1.54 compared with white women (95% CI 1.4 to 1.6).

Dr. Maxwell presented data from a retrospective review of a Gynecologic Oncology Group clinical trial of postoperative estrogen replacement therapy in women with stage I-II endometrial cancer. The trial included 110 black patients and 1,049 white patients. The primary endpoint was recurrence-free survival.

The analysis showed a significantly increased risk of recurrence in blacks randomized to estrogen-replacement therapy. Dr. Maxwell said five of 56 black patients in the estrogen-replacement therapy arm had recurrent disease compared with eight of 521 white patients. The difference translated into a relative risk of 11.2 for black versus white women (95% CI 2.86 to 43.59, P=0.0005).

Mortality data also revealed an increased hazard for black patients. After adjustment for age, body mass index, and tumor grade, black women had a relative risk of mortality of 2.24 (95% CI 1.01 to 4.94, P=0.047).

Accessibility Statement

At MedPage Today, we are committed to ensuring that individuals with disabilities can access all of the content offered by MedPage Today through our website and other properties. If you are having trouble accessing www.medpagetoday.com, MedPageToday's mobile apps, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.